SCHEMBL6510375

SCHEMBL6510375

Cc1[nH]nc2c1c(=O)n(CCCN)c1cc(C(=O)O)ccc21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 12/20 0.63
KCNH2 Q12809 2/20 0.58
PARP1 P09874 1/20 0.46
AURKA O14965 1/20 0.45
KDR P35968 1/20 0.45
AURKB Q96GD4 1/20 0.45
CSNK2A1 P68400 2/20 0.43
CSNK2A2 P19784 1/20 0.43
CSNK2B P67870 1/20 0.43
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HASPIN Q8TF76 1/20 0.38
METAP2 P50579 1/20 0.37
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
JAK3 P52333 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6507644 0.92 CHEK1 (0.72) CHEK1KCNH2PARP1AURKAKDR
SCHEMBL6508522 0.89 CHEK1 (0.60) CHEK1KCNH2AURKAKDRAURKB
SCHEMBL6513174 0.84 CHEK1 (0.84) CHEK1KCNH2AURKAKDRAURKB
SCHEMBL6514092 0.84 CHEK1 (0.67) CHEK1KCNH2AURKAKDRAURKB
SCHEMBL6507581 0.81 CHEK1 (0.72) CHEK1KCNH2AURKAKDRAURKB
SCHEMBL4004208 0.81 CHEK1 (0.71) CHEK1KCNH2AURKAKDRAURKB
SCHEMBL6515391 0.80 CHEK1 (0.77) CHEK1KCNH2AURKAKDRAURKB
SCHEMBL6510579 0.79 CHEK1 (0.80) CHEK1KCNH2AURKAKDRAURKB
SCHEMBL6512695 0.78 CHEK1 (0.78) CHEK1KCNH2AURKAKDRAURKB
SCHEMBL6517703 0.78 CHEK1 (1.00) CHEK1KCNH2AURKAKDRAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 CHEK1 3/4885KCNH2 3052/4885PARP1 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.